Cupric Chloride
CAS 7447-39-4
Cupric Chloride (CAS 7447-39-4) is a pharmaceutical compound with 0 bioactivity targets and 2 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Kounis syndrome | 12 | 63.386 | 10069167 |
| Reversible cerebral vasoconstriction syndrome | 6 | 29.287 | 10073240 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CUPRIC CHLORIDE | 21833 | SU | MTHSPL |
| cupric chloride | 21833 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cupric Chloride used for in pharmaceutical contexts?
Cupric Chloride (CAS 7447-39-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cupric Chloride?
Cupric Chloride has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Kounis syndrome, Reversible cerebral vasoconstriction syndrome, Anaemia, COVID-19, Cellulitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cupric Chloride also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cupric Chloride with EU status "prohibited".
What clinical phase is Cupric Chloride in?
No phase 1-4 clinical development badge is rendered for Cupric Chloride because the matched compound identifier rows do not contain a max-phase value.